Adam Fein, PhD
Founder & PresidentPembroke Consulting Inc
Adam Fein, PhD, is the Founder and President of Pembroke Consulting, Inc., a Philadelphia-based management advisory and business research firm. Dr. Fein is one of the country’s foremost experts on pharmacy economics and the pharmaceutical supply chain. He provides strategic advisory services to a diverse mix of clients, including pharmaceutical manufacturers, pharmacy benefit managers, supply chain technology companies, law firms, health care providers, trade associations, and institutional investors. Dr. Fein has published over 100 academic and industry articles, authored or edited nine books, and currently writes the popular blog DrugChannels.net. He is frequently sought by the media for his industry expertise and has been quoted in many leading national publications. Dr. Fein serves as the first Fellow of the NAW Institute for Distribution Excellence and is on the Advisory Boards of Supply Chain Equity Partners, Secure Symbology, IntegriChain, and Pharmaceutical Commerce magazine. (This is me - Update Profile)
| 1997 - present | Founder & President Pembroke Consulting Inc |
|---|
GLG Study Groups with Adam Fein, PhD(?)
| Study Group Name | Members |
|---|---|
| Generic Drug Economic Experts | 635 |
| Average Wholesale Pricing Economic Experts: Healthcare Consultants | 18 |
| Medicare Experts | 427 |
| Biopharmaceutical Pricing Trend Experts (US) | 25 |
GLG NewsSM Analyses by Adam Fein, PhD(?)
Representatives Steve Buyer (R-IN), Gene Green (D-TX), Jim Matheson (D-UT), and Mike Rogers (R-MI) co-sponsored H.R. 5839 Safeguarding America’s Pharmaceuticals Act of 2008. H.R. 5839 was going to be incorporated into other related FDA legislation, but intense behind-the scenes lobbying by the pharmacy...
Implementation of California’s e-pedigree law has (probably) been pushed back to 2015. The widespread industry support for the bill makes me believe that the 2015 date might actually stick. The more realistic timeline should encourage pharmaceutical manufacturers to get serious about mass serialization...
State Senator Mark Ridley-Thomas’ editorial argues California needs its own pharmaceutical supply chain security laws because the Federal government has failed to implement the Prescription Drug Marketing Act (PDMA). However, it does not necessarily follow that every individual state pharmacy board...
A new report from Accenture attempts to assess the financial costs of implementing a serialized track-and-trace system for the U.S. pharmacy supply chain. But even if we assume that Accenture did a credible and impartial job building their pharmacy cost models, the estimates in this report reflect an...
GLG InstituteSM Seminars with Adam Fein, PhD(?)
View all GLG InstituteSM Seminars in Healthcare
Request a project with Adam Fein, PhD
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms